Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
Want to see HOWL full AI Analyst Report?
HOWL Stock Chart & Stats
$0.92
-$0.04(-2.90%)
At close: 4:00 PM EST
$0.92
-$0.04(-2.90%)
Day’s Range― - ―
52-Week Range$0.53 - $2.38
Previous CloseN/A
Volume113.58K
Average Volume (3M)1.22M
Market Cap
$44.69M
Enterprise Value$24.92M
Total Cash (Recent Filing)$57.05M
Total Debt (Recent Filing)$37.67M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding48,596,817
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.48
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-20.23
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$7.00Price Target Upside660.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Maturing Clinical DataExtended cash runway combined with maturing clinical data from early trials could clarify the company's value proposition and increase investor confidence if results support advancement.
T-cell Engager StrategyStrategic pivot to T cell engagers aligns with strong investor appetite for the modality and may create nearer-term opportunities for licensing, partnerships, or market re-rating.
Tumor-activated Masking TechnologyProprietary tumor-activated masking technology appears to reduce off-target toxicities and improve safety, which could enhance clinical attractiveness and partnership interest if safety signals persist.
Bears Say
Executive DeparturesDepartures of the chief financial officer and chief medical officer create leadership gaps that increase uncertainty around execution and could hinder financing or partner negotiations.
Investor Skepticism On Cytokine TolerabilityHistorical difficulties improving cytokine tolerability have left investors skeptical, which could pressure valuation until clear safety improvements are demonstrated.
Workforce Reduction And Funding RiskLarge workforce reductions intended to conserve cash signal potential difficulties securing external funding and raise the risk of development delays or program discontinuations.
Werewolf Therapeutics News
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.53 and its highest was $2.38 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $44.69M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 20 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Mar 27, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.345 by $0.145.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 48,596,817 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.345. Following the earnings report the stock price went down -9.618%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Werewolf Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (660.87% Upside)
$7.00 (660.87% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.95%
12-Months-Change
Fundamentals
Return on Equity
-122.43%
Trailing 12-Months
Asset Growth
-39.78%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Stock 12 Month Forecast
Average Price Target
$7.00
▲(660.87% Upside)
Technical Analysis
CervoMed
―
NRX Pharmaceuticals
―
Kalaris Therapeutics
―
Coeptis Therapeutics Holdings
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
42.14% Insiders
3.10% Mutual Funds
21.53% Other Institutional Investors
30.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---